Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2014 | ASH 2014: The management of CLL

George Follows • 9 Apr 2015
ASH 2014
Chronic Lymphocytic Leukemia

Dr George Follows provides an overview of results of clinical trials in chronic lymphocytic leukemia (CLL) presented at the 2014 American Society of Hematology (ASH) Annual Meeting. He considers the clinical value of maintenance therapy with anti-CD20 monoclonal antibodies in CLL and molecularity defined subtypes in CLL.

More from George Follows

Five-year follow up of the UK CLL Forum ibrutinib data
3:58
Five-year follow up of the UK CLL Forum ibrutinib data
George Follows • 20 Sep 2019
Evolving management of relapsed CLL: UK CLL Forum analysis of ibrutinib at first relapse
1:21
Evolving management of relapsed CLL: UK CLL Forum analysis of ibrutinib at first relapse
George Follows • 2 May 2018
PEP-C for treatment of relapsed/refractory lymphoma
1:11
PEP-C for treatment of relapsed/refractory lymphoma
George Follows • 2 May 2018
MURANO study: exciting times in CLL
2:06
MURANO study: exciting times in CLL
George Follows • 9 Dec 2017

Related Videos

Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
George Follows • 6 Dec 2025
Translating academic-center data to community settings to improve the adoption of bispecifics
1:54
Translating academic-center data to community settings to improve the adoption of bispecifics
George Follows • 8 Dec 2025
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
1:30
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
George Follows • 7 Dec 2025
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
0:53
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
George Follows • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals